News Releases

Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced it has successfully supported 300 completed submissions to

PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Morgan Stanley 21 st Annual Global Healthcare Conference  Date and Time: Tuesday,

Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced

Provides Update to Full Year 2023 Financial Guidance PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023. Second Quarter Highlights: Revenue was $90.5

Software will aid optimizing pre-clinical data management in accordance with global standards and guidelines. SEOUL, South Korea --(BUSINESS WIRE)--Aug. 3, 2023-- Certara, Inc. (Nasdaq: CERT), a global leader in Biosimulation, today announced that a Korea Institute of Toxicology (KIT) have decided

PRINCETON, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2023 after the market close on Wednesday, August 9 th , 2023.

PRINCETON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference. Company management will present at 1:30PM ET on Wednesday, June 7 th , 2023.

Reiterates 2023 Financial Guidance PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2023. First Quarter Highlights: Revenue was $90.3 million, compared to $81.6

Asserts Certara’s leadership in advancing the development and approval of new drugs for patients PRINCETON, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S.

PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8 th , 2023.